Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Fineline Cube Mar 31, 2026
Company Deals

AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations

Fineline Cube Mar 31, 2026
Company Deals

Shaanxi Micot Files HKSE Listing Application to Advance Bifunctional Peptide Drug Pipeline

Fineline Cube Mar 31, 2026
Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Policy / Regulatory

NMPA Finalizes Conditional Drug Approval Framework to Accelerate Access to Critical Medicines

Fineline Cube Mar 31, 2026
Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Fineline Cube Mar 31, 2026
Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Fineline Cube Mar 31, 2026
Company

Legend Biotech Reports Q2 Revenue Growth of 36.7% and H1 Growth of 60.4%

Fineline Cube Aug 12, 2025

China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2)...

Company

Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition

Fineline Cube Aug 12, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...

Company Drug

Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA

Fineline Cube Aug 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...

Policy / Regulatory

Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone

Fineline Cube Aug 12, 2025

The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...

Legal / IP

CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer

Fineline Cube Aug 12, 2025

CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...

Others

Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach

Fineline Cube Aug 12, 2025

Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed...

Company Drug

Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema

Fineline Cube Aug 12, 2025

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...

Company Drug

Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer

Fineline Cube Aug 12, 2025

Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...

Company Medical Device

J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants

Fineline Cube Aug 12, 2025

US major Johnson & Johnson MedTech announced that its MENTOR MemoryGel Xtra Breast Implants have...

Company Drug

Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer

Fineline Cube Aug 12, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced the first patient dosing in the...

Company Deals

Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004

Fineline Cube Aug 12, 2025

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced on August 11, 2025, that...

Company Deals

Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China

Fineline Cube Aug 12, 2025

On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive...

Company Deals

Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D

Fineline Cube Aug 12, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a...

Company

Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition

Fineline Cube Aug 11, 2025

Germany-based multinational Merck KGaA (ETR: MRK) reported Q2 2025 financial results, which were significantly affected...

Company Drug

Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma

Fineline Cube Aug 11, 2025

China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase...

Company Drug

Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment

Fineline Cube Aug 11, 2025

China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...

Company Drug

Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment

Fineline Cube Aug 11, 2025

Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed...

Company Drug

Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment

Fineline Cube Aug 11, 2025

German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...

Company Deals

Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets

Fineline Cube Aug 11, 2025

China-based Lepu Biopharma Co., Ltd. (HKG: 2157) announced on August 1, 2025, that it has...

Company Deals

Tigermed Partners with Africare BioPharma to Enhance Africa’s Clinical Research Capabilities

Fineline Cube Aug 11, 2025

On August 8, 2025, Hangzhou Tigermed Consulting (SHE: 300347, HKG: 3347), a China-based contract research...

Posts pagination

1 … 94 95 96 … 644

Recent updates

  • ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma
  • Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial
  • Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels
  • Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership
  • AIM Vaccine Plans Beijing Stock Exchange IPO to Strengthen Capital Base and Expand Operations
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

ImmuneOnco Doses First Patient in Phase III Trial of World’s First CD47/CD20 Bispecific for Follicular Lymphoma

Company Drug

Merck’s Oral PCSK9 Inhibitor Enlicitide Shows Superior LDL-C Reduction in CORALreef AddOn Trial

Company Drug

Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels

Company Deals

Biocytogen Licenses RenNano Antibody Platform to Japan’s Taisho Pharmaceutical in Strategic Partnership

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.